| Issue Date | Title | Author(s) |
| 2023 | Association Between Prenatal Per- and Polyfluoroalkyl Substance Exposure and Maternal Serum Total Bile Acid Levels During Pregnancy: Effect Modification by Infant Sex and Maternal Prepregnancy BMI | Liao, Qian; Huang, Huishen; Tang, Peng; Liang, Jun; Chen, Jiehua; Lei, Lei; Song, Yanye; Pan, Dongxiang; Lin, Mengrui; Lv, Fangfang; Liang, Xue; Zeng, Xiaoyun; Liu, Shun; Huang, Dongping; Qiu, Xiaoqiang |
| Mar-2024 | Associations of prenatal exposure to per- and polyfluoroalkyl substances and fetal sex hormones in the Guangxi Zhuang Birth Cohort Study: Greater effect of long-chain PFAS | Liao, Qian; Huang, Huishen; Tang, Peng; Liang, Jun; Chen, Jiehua; Mu, Changhui; Pan, Dongxiang; Lv, Fangfang; Zhou, Lihong; Long, Jinghua; Chen, Qian; Zeng, Xiaoyun; Liu, Shun; Huang, Dongping; Qiu, Xiaoqiang |
| Feb-2022 | Attitudes of Chinese Patients with Non-alcoholic Fatty Liver Disease Toward Participation in Clinical Trials from a National Multicenter Survey | Huang, Rui; Rao, Huiying; Lv, Fangfang; Nan, Yuemin; Ren, Wanhua; Huang, Yan; Li, Jun; Tang, Hong; Huang, Yuan; Chalasani, Naga; Wei, Lai |
| 2018 | The Attitudes of Patients with Nonalcoholic Fatty Liver Disease Towards Participation in Placebo-Controlled Clinical Trials: Results from a Multicenter Survey | Huang, Rui; Rao, Huiying; Lv, Fangfang; Nan, Yuemin; Ren, Wanhua; Huang, Yan; Li, Jun; Tang, Hong; Huang, Yuan; Chalasani, Naga P.; Wei, Lai |
| 2018 | The Attitudes of Patients with Nonalcoholic Fatty Liver Disease Towards Participation in Placebo-Controlled Clinical Trials: Results from a Multicenter Survey | Huang, Rui; Rao, Huiying; Lv, Fangfang; Nan, Yuemin; Ren, Wanhua; Huang, Yan; Li, Jun; Tang, Hong; Huang, Yuan; Chalasani, Naga P.; Wei, Lai |
| 2019 | Incidence and Etiology of Drug-Induced Liver Injury in Mainland China | Shen, Tao; Liu, Yingxia; Shang, Jia; Xie, Qing; Li, Jun; Yan, Ming; Xu, Jianming; Niu, Junqi; Liu, Jiajun; Watkins, Paul B.; Aithal, Guruprasad P.; Andrade, Raul J.; Dou, Xiaoguang; Yao, Lvfeng; Lv, Fangfang; Wang, Qi; Li, Yongguo; Zhou, Xinmin; Zhang, Yuexin; Zong, Peilan; Wan, Bin; Zou, Zhengsheng; Yang, Dongliang; Nie, Yuqiang; Li, Dongliang; Wang, Yuya; Han, Xi'an; Zhuang, Hui; Mao, Yimin; Chen, Chengwei |
| 2023 | Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma | Song, Yuqin; Zhou, Keshu; Yang, Shenmiao; Hu, Jianda; Zou, Dehui; Gao, Sujun; Pan, Ling; Wang, Tingyu; Yang, Haiyan; Zhang, Huilai; Zhou, Daobin; Ji, Jie; Xu, Wei; Feng, Ru; Jin, Jie; Lv, Fangfang; Huang, Haiwen; Fan, Xiaosi; Xu, Sheng; Zhu, Jun |
| 2023 | Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis | Song, Yuqin; Zhou, Keshu; Zou, Dehui; Li, Dengju; Hu, Jianda; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Jin, Jie; Lv, Fangfang; Feng, Ru; Gao, Sujun; Zhou, Daobin; Tam, Constantine S.; Simpson, David; Wang, Michael; Phillips, Tycel J.; Opat, Stephen; Fang, Cheng; Sun, Shaohui; Zhu, Jun |
| 15-Nov-2022 | Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis | Song, Yuqin; Zhou, Keshu; Zou, Dehui; Li, Dengju; Hu, Jianda; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Jin, Jie; Lv, Fangfang; Feng, Ru; Gao, Sujun; Zhou, Daobin; Tam, Constantine S.; Simpson, David; Wang, Michael L.; Phillips, Tycel J.; Opat, Stephen; Fang, Cheng; Sun, Shaohui; Zhu, Jun |
| 2018 | Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial | Song, Yuqin; Zhou, Keshu; Zou, Dehui; Zhou, Jianfeng; Hu, Jianda; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Jin, Jie; Lv, Fangfang; Feng, Ru; Gao, Sujun; Zhou, Daobin; Guo, Haiyi; Wang, Aihua; Hilger, James; Huang, Jane; Novotny, William; Osman, Muhtar; Zhu, Jun |
| 2018 | Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study | Song, Yuqin; Gao, Quanli; Zhang, Huilai; Fan, Lei; Zhou, Jianfeng; Zou, Dehui; Li, Wei; Yang, Haiyan; Liu, Ting; Wang, Quanshun; Lv, Fangfang; Yang, Yu; Guo, Haiyi; Yang, Liudi; Elstrom, Rebecca; Huang, Jane; Novotny, William; Wei, Vivian; Zhu, Jun |
| 20-May-2020 | Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: Results from a phase II, single-arm, multicenter, study. | Yang, Haiyan; Xiang, Bing; Song, Yuqin; Zhang, Huilai; Zhao, Weili; Zou, Dehui; Lv, Fangfang; Bai, Ou; Liu, Aichun; Li, Caixia; Tan, Ziwen; Wang, Weige; Guo, Haiyi; Novotny, William; Huang, Jane E.; Li, Yufu |
